Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Incontinence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Erectile Dysfunction 1Carcinoma 1Adenocarcinoma 1

Interventions

Cisplatin 15pembrolizumab 14Magnetic Resonance Spectroscopy 13Specimen Handling 12Carboplatin 10Platinum 81,2-diaminocyclohexaneplatinum II citrate 8Paclitaxel 7durvalumab 6Radiotherapy, Intensity-Modulated 6Cetuximab 6cemiplimab 5Radiotherapy 5Radiation 5Pemetrexed 5Nivolumab 5Biopsy 5Ipilimumab 4Fluorouracil 41-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4(225)Ac-DOTA-c(RGDyK) 4poly ICLC 3osimertinib 3atezolizumab 3Taxes 3Oxaliplatin 3Docetaxel 3ipatasertib 2fludarabine phosphate 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Tadalafil × 90 days × Clear all
NCT05014776 2026-04-28

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
17 enrolled 8 charts
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡